Arndt Vogel· @ArndtVogel · X·· 2 天前评分70
正文 · 原文
AGITG MASTERPLAN ph II study: mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced PDAC
#ESMO26 #ESMOAmbassadors
👉 Local recurrence: 20 vs 52%
👉 mPFS: 11.3 vs 6.3 mo
👉 mOS: 22 vs 14 mo
🧐Provides evidence for SBRT
@myESMO @ASCO
487 浏览 · 6 赞 · 4 转发 · 0 回复
会议摘要
3136RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
https://esmocongress.esmo.org来源：Arndt Vogel · x.com